AlphaMark Advisors’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

AlphaMark Advisors’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$4K	Hold	14,007	–	–	﹤0.01%	541
2024 Q3	$4K	Hold	14,007	–	–	﹤0.01%	598
2024 Q2	$6K	Hold	14,007	–	–	﹤0.01%	603
2024 Q1	$7K	Buy	+14,007	New	+$7K	﹤0.01%	586
2023 Q4	–	Sell	-14,007	Closed	-$13K	–	826
2023 Q3	$13K	Hold	14,007	–	–	0.01%	484
2023 Q2	$8K	Hold	14,007	–	–	﹤0.01%	448
2023 Q1	$9K	Hold	14,007	–	–	﹤0.01%	430
2022 Q4	$11K	Hold	14,007	–	–	0.01%	370
2022 Q3	$10K	Hold	14,007	–	–	0.01%	419
2022 Q2	$9K	Hold	14,007	–	–	﹤0.01%	414
2022 Q1	$10K	Hold	14,007	–	–	﹤0.01%	408
2021 Q4	$10K	Hold	14,007	–	–	﹤0.01%	404
2021 Q3	$18K	Hold	14,007	–	–	0.01%	348
2021 Q2	$21K	Buy	+14,007	New	+$21K	0.01%	331

Other funds holding NWBO

MSAM

Moloney Securities Asset Management Manchester, Missouri $840M AUM 18.11% 1-Year Est. Return

VWA

VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return

OCG

Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return

WJWM

Williams Jones Wealth Management New York $8.14B AUM 19.32% 1-Year Est. Return

EFG

Ethos Financial Group King Of Prussia, Pennsylvania $1.37B AUM 19.43% 1-Year Est. Return

Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return

AMG

Advisors Management Group La Crosse, Wisconsin $549M AUM 29.35% 1-Year Est. Return

KLCM Advisors Milwaukee, Wisconsin $1.19B AUM 34.45% 1-Year Est. Return

AlphaMark Advisors's NWBO Position: Q4 2024 in Review

AlphaMark Advisors held its Northwest Biotherapeutics, Inc. Common stock (NWBO) position steady in Q4 2024 at 14,007 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #541.

AlphaMark Advisors first reported a position in NWBO in Q2 2021 and has held it in 14 quarters since. The position peaked at $21K in Q2 2021. 11 funds tracked by Wall St. Rank hold NWBO as of Q4 2024.

AlphaMark Advisors held 14,007 shares of Northwest Biotherapeutics, Inc. Common stock worth $4K as of Q4 2024.
AlphaMark Advisors left its Northwest Biotherapeutics, Inc. Common stock share count unchanged in Q4 2024.
Northwest Biotherapeutics, Inc. Common stock made up ﹤0.01% of AlphaMark Advisors's portfolio in Q4 2024, its #541 holding.
AlphaMark Advisors first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2021 and has held it in 14 quarters since.
AlphaMark Advisors's Northwest Biotherapeutics, Inc. Common stock position peaked at $21K in Q2 2021.
11 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2024.

Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.